|
|
|
|
PHNO[(+)-4-propyl-9-hydroxynaphthoxazine]is a chemically novel and highly potent dopamine(D2)receptor agonist without D1 activity.It had significant antiparkinsonism effects when used as open-label monotherapy in ten patients who were Hoehn and Yahr stage 2 or 3.The standard formulation of PHNO produced a 3-to 4-hour therapeutic effect in most patients;the response to the time-release formulation lasted up to 10 hours.Side effects were similar to those of other dopamine agonists but dyskinesia was seen in only one patient. |
|